Study of PaQ™ (a Simple Patch on Insulin Delivery Device) in Patients With Type 2 Diabetes Mellitus
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
PaQ™ insulin infusion device
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Male/female patient's ≥ 30 ≤ 65 years of age.
- Clinical confirmation of T2DM diagnosis by history and medication usage or glucose tolerance test.
- Currently treated with insulin using a basal/bolus regimen with or without concurrent use of OADs (metformin and/or glitazone).
- Currently on a stable insulin regimen "as judged by the investigator" (using an estimate of their basal dose of insulin does not fluctuate by more than ±10% every day) and if he/she is receiving a concurrent oral agent, the dose has remained unchanged for the last 30 days.
- Currently uses between 20 to 50 units/day basal insulin.
Exclusion Criteria:
- Uncontrolled hyperglycemia, HbA1c > 9.0% requiring adjustment to his/her insulin regimen.
- Treated with premixed insulin, or neutral protamine hagedorn (NPH)/glargine/detemir insulin without use of bolus/meal time insulin.
- Patient has had an episode of severe (assisted) hypoglycemia within the past 30 days.
- Currently treated with sulfonylurea or incretin-based therapy [glucagon-like peptide-1(GLP-1) agonist or dipeptidyl peptidase-4 (DPP-4) inhibitor].
- Total daily dose (TDD) of insulin is >100 units/day.
- Have a meal-time bolus doses that exceeds the capacity of the bolus Insulin Reservoir at any given meal.
- Have existing dermal irritation on their abdomen or have known hypersensitivity to skin adhesives.
- Taking or has taken prednisone or cortisone medications in the previous 30 days.
- Pregnant or is planning to become pregnant during the study period.
- Has severe medical or psychological condition(s) or chronic conditions/infections that in the opinion of the Investigator would compromise the patient's safety or successful participation in the study.
- Unable to follow the study clinical investigational plan (CIP)
Sites / Locations
- Medical University of Graz
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
PaQ™ insulin infusion device
Arm Description
PaQ™ insulin infusion device which delivers rapid acting insulin.
Outcomes
Primary Outcome Measures
Patients ability to successfully assemble, fill, prime, apply and use the PaQ™ device
Secondary Outcome Measures
Insulin usage
Average daily amount of basal insulin and meal time bolus insulin will be calculated
7-point blood glucose reading
7 - points are pre and 1.5 hours post each meal and at bedtime
Glucose variability
Continuous glucose monitoring (CGM) will be performed. Data stored in the CGM will be transferred to a computer at the end of each study period. Glucose variability during each time period will be calculated.
Glucose exposure
Continuous glucose monitoring (CGM) will be performed. Data stored in the CGM will be transferred to a computer at the end of each study period. Glucose exposure during each time period will be calculated.
Glucose Stability
Continuous glucose monitoring (CGM) will be performed. Data stored in the CGM will be transferred to a computer at the end of each study period. Glucose stability during each time period will be calculated.
Infection at cannula insertion site
Occurence of adverse experiences and the number and severity of hypoglycemic episodes
Quality of Life Questionnaire
Dermal Irritation
Full Information
NCT ID
NCT01535612
First Posted
September 2, 2011
Last Updated
July 25, 2016
Sponsor
CeQur Corporation
Collaborators
International Diabetes Center at Park Nicollet
1. Study Identification
Unique Protocol Identification Number
NCT01535612
Brief Title
Study of PaQ™ (a Simple Patch on Insulin Delivery Device) in Patients With Type 2 Diabetes Mellitus
Official Title
A Study Evaluating the Feasibility of Use and Performance of PaQ™ in Patients With Type 2 Diabetes Mellitus Who Are Currently Treated With Basal/Bolus Insulin Therapy
Study Type
Interventional
2. Study Status
Record Verification Date
July 2016
Overall Recruitment Status
Completed
Study Start Date
March 2012 (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
September 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CeQur Corporation
Collaborators
International Diabetes Center at Park Nicollet
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the ability of a patient, who has type 2 diabetes (T2DM) who is currently treated with basal/bolus insulin therapy, to use PaQ™ (a simple patch on insulin delivery device) to control his/her blood glucose.
Detailed Description
This is a single center, open label, feasibility of use and performance evaluation of PaQ™ (using insulin aspart) in patients with T2DM who are currently receiving basal/bolus insulin therapy with or without oral anti-diabetic drugs (OADs) for glycemic control. The patient's participation in the study is comprised of four phases: screening, baseline evaluation, transition to PaQ™ use, and PaQ™ treatment period. The use of these phases will allow an orderly transition to PaQ™ treatment as well as a reliable construct from which to interpret the final data.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PaQ™ insulin infusion device
Arm Type
Experimental
Arm Description
PaQ™ insulin infusion device which delivers rapid acting insulin.
Intervention Type
Device
Intervention Name(s)
PaQ™ insulin infusion device
Intervention Description
Basal/bolus insulin therapy administered by CSII for 4 weeks. First two weeks is transition period to identify correct basal rate for the patient, second 2 weeks is treatment period to evaluate efficacy of CSII device.
Primary Outcome Measure Information:
Title
Patients ability to successfully assemble, fill, prime, apply and use the PaQ™ device
Time Frame
End of two week transition period
Secondary Outcome Measure Information:
Title
Insulin usage
Description
Average daily amount of basal insulin and meal time bolus insulin will be calculated
Time Frame
End of two baseline period and end of 2 week treatment period
Title
7-point blood glucose reading
Description
7 - points are pre and 1.5 hours post each meal and at bedtime
Time Frame
Twice per week during baseline period (weeks 1 & 2) and PaQ™ Treatment period (weeks 5 & 6)
Title
Glucose variability
Description
Continuous glucose monitoring (CGM) will be performed. Data stored in the CGM will be transferred to a computer at the end of each study period. Glucose variability during each time period will be calculated.
Time Frame
During baseline and PaQ™ treatment period
Title
Glucose exposure
Description
Continuous glucose monitoring (CGM) will be performed. Data stored in the CGM will be transferred to a computer at the end of each study period. Glucose exposure during each time period will be calculated.
Time Frame
During baseline and PaQ™ treatment period
Title
Glucose Stability
Description
Continuous glucose monitoring (CGM) will be performed. Data stored in the CGM will be transferred to a computer at the end of each study period. Glucose stability during each time period will be calculated.
Time Frame
During baseline and PaQ™ Treatment Period
Title
Infection at cannula insertion site
Time Frame
During transition and PaQ™ treatment period
Title
Occurence of adverse experiences and the number and severity of hypoglycemic episodes
Time Frame
During baseline, transition and PaQ™ treatment period
Title
Quality of Life Questionnaire
Time Frame
At the end of the study
Title
Dermal Irritation
Time Frame
During transition and PaQ™ treatment period
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male/female patient's ≥ 30 ≤ 65 years of age.
Clinical confirmation of T2DM diagnosis by history and medication usage or glucose tolerance test.
Currently treated with insulin using a basal/bolus regimen with or without concurrent use of OADs (metformin and/or glitazone).
Currently on a stable insulin regimen "as judged by the investigator" (using an estimate of their basal dose of insulin does not fluctuate by more than ±10% every day) and if he/she is receiving a concurrent oral agent, the dose has remained unchanged for the last 30 days.
Currently uses between 20 to 50 units/day basal insulin.
Exclusion Criteria:
Uncontrolled hyperglycemia, HbA1c > 9.0% requiring adjustment to his/her insulin regimen.
Treated with premixed insulin, or neutral protamine hagedorn (NPH)/glargine/detemir insulin without use of bolus/meal time insulin.
Patient has had an episode of severe (assisted) hypoglycemia within the past 30 days.
Currently treated with sulfonylurea or incretin-based therapy [glucagon-like peptide-1(GLP-1) agonist or dipeptidyl peptidase-4 (DPP-4) inhibitor].
Total daily dose (TDD) of insulin is >100 units/day.
Have a meal-time bolus doses that exceeds the capacity of the bolus Insulin Reservoir at any given meal.
Have existing dermal irritation on their abdomen or have known hypersensitivity to skin adhesives.
Taking or has taken prednisone or cortisone medications in the previous 30 days.
Pregnant or is planning to become pregnant during the study period.
Has severe medical or psychological condition(s) or chronic conditions/infections that in the opinion of the Investigator would compromise the patient's safety or successful participation in the study.
Unable to follow the study clinical investigational plan (CIP)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Pieber, MD
Organizational Affiliation
Medical University of Graz
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University of Graz
City
Graz
ZIP/Postal Code
A-8036
Country
Austria
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Published in Diabetes Care - Volume 37, May 2014, pages 1476-1479
Citations:
PubMed Identifier
24598242
Citation
Mader JK, Lilly LC, Aberer F, Korsatko S, Strock E, Mazze RS, Damsbo P, Pieber TR. A feasibility study of a 3-day basal-bolus insulin delivery device in individuals with type 2 diabetes. Diabetes Care. 2014 May;37(5):1476-9. doi: 10.2337/dc13-2238. Epub 2014 Mar 5.
Results Reference
result
Learn more about this trial
Study of PaQ™ (a Simple Patch on Insulin Delivery Device) in Patients With Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs